Geode Capital Management’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
Other funds holding PLX
Geode Capital Management's PLX Position: Q3 2026 in Review
Geode Capital Management increased its Protalix BioTherapeutics (PLX) stake by 1.7% in Q3 2026, buying an estimated $42.6K and bringing the position to 997,128 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3090.
Geode Capital Management first reported a position in PLX in Q2 2023 and has held it in 10 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.
- Geode Capital Management held 997,128 shares of Protalix BioTherapeutics worth $2.75M as of Q3 2026.
- Geode Capital Management bought 17,133 Protalix BioTherapeutics shares in Q3 2026, an estimated $42.6K.
- Protalix BioTherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3090 holding.
- Geode Capital Management first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 10 quarters since.
- 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.
Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.